drugset / Trial / NCT01545648

Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer

NCT01545648

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see whether taking denosumab for 12 months in women with a significant number of disseminated tumor cells in the bone marrow can reduce the number of these cells below a significant level.

Timeline

Start
2012-11-01
Primary completion
2015-06-09
Completion
2016-06-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 120 mg Subcutaneous